JOP20210241A1 - مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان - Google Patents

مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان

Info

Publication number
JOP20210241A1
JOP20210241A1 JOP/2021/0241A JOP20210241A JOP20210241A1 JO P20210241 A1 JOP20210241 A1 JO P20210241A1 JO P20210241 A JOP20210241 A JO P20210241A JO P20210241 A1 JOP20210241 A1 JO P20210241A1
Authority
JO
Jordan
Prior art keywords
compounds useful
anticancer agents
tricyclic compounds
fused tricyclic
relates
Prior art date
Application number
JOP/2021/0241A
Other languages
English (en)
Inventor
Kurt Gordon Pike
Iain Simpson
Jason Grant Kettle
Michael Steven Bodnarchuk
Scott Boyd
Oliver Ross Steward
Christopher Phillips
Doyle Joseph Cassar
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20210241A1 publication Critical patent/JOP20210241A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

تتعلق المواصفة بمركبات لها الصيغة (A) وأملاح مقبولة صيدلانياً منها. تتعلق المواصفة أيضاً بعمليات ومركبات وسطية تُستخدم لتحضيرها، تركيبات صيدلانية تشملها واستخدامها في معالجة اضطرابات تكاثر الخلية.
JOP/2021/0241A 2019-03-05 2020-03-03 مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان JOP20210241A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813885P 2019-03-05 2019-03-05
US201962951146P 2019-12-20 2019-12-20
PCT/EP2020/055551 WO2020178282A1 (en) 2019-03-05 2020-03-03 Fused tricyclic compounds useful as anticancer agents

Publications (1)

Publication Number Publication Date
JOP20210241A1 true JOP20210241A1 (ar) 2023-01-30

Family

ID=69740367

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0241A JOP20210241A1 (ar) 2019-03-05 2020-03-03 مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان

Country Status (23)

Country Link
US (1) US20220204527A1 (ar)
EP (1) EP3935060B1 (ar)
JP (1) JP7453989B2 (ar)
KR (1) KR20210135539A (ar)
CN (1) CN113508118B (ar)
AU (1) AU2020231045B2 (ar)
BR (1) BR112021017408A2 (ar)
CA (1) CA3131156A1 (ar)
CL (1) CL2021002296A1 (ar)
CO (1) CO2021012381A2 (ar)
CR (1) CR20210504A (ar)
DO (1) DOP2021000183A (ar)
EC (1) ECSP21073246A (ar)
IL (1) IL285761B1 (ar)
JO (1) JOP20210241A1 (ar)
MA (1) MA55198A (ar)
MX (1) MX2021010674A (ar)
PE (1) PE20220140A1 (ar)
SG (1) SG11202109451TA (ar)
TW (1) TW202100532A (ar)
UY (1) UY38602A (ar)
WO (1) WO2020178282A1 (ar)
ZA (1) ZA202106192B (ar)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
EP4034123A4 (en) 2019-09-24 2023-11-01 Mirati Therapeutics, Inc. COMBINATION THERAPIES
MX2022005053A (es) 2019-10-28 2022-05-18 Merck Sharp & Dohme Llc Inhibidores de peque?as moleculas de mutante g12c de kras.
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
UA128806C2 (uk) 2019-12-11 2024-10-23 Елі Ліллі Енд Компані Інгібітори kras g12c
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
CA3183032A1 (en) 2020-06-18 2021-12-23 Mallika Singh Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
CN114437107A (zh) * 2020-11-06 2022-05-06 江苏先声药业有限公司 哌嗪类化合物及其应用
CN114539286B (zh) * 2020-11-24 2024-02-02 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
TW202235082A (zh) 2020-12-04 2022-09-16 美商美國禮來大藥廠 Ｋｒａｓ ｇ１２ｃ抑制劑
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
BR112023020773A2 (pt) * 2021-04-08 2024-01-30 Genentech Inc Compostos, composição farmacêutica, métodos para tratar câncer, para regular a atividade de uma proteína mutante, para inibir a proliferação de uma população celular, para preparar uma proteína mutante e para inibir metástase de tumor, uso de um composto e processo para sintetizar um composto
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
EP4421076A1 (en) 2021-10-22 2024-08-28 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
WO2023072297A1 (zh) * 2021-11-01 2023-05-04 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023126822A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
WO2023168036A1 (en) 2022-03-04 2023-09-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024213699A1 (en) 2023-04-14 2024-10-17 Astrazeneca Ab Combinations of kras inhibitor and atr inhibitor for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318412A1 (en) * 2006-07-11 2009-12-24 Takahiro Matsumoto Tricyclic heterocyclic compound and use thereof
NO2714752T3 (ar) * 2014-05-08 2018-04-21
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AR111776A1 (es) * 2017-05-11 2019-08-21 Astrazeneca Ab Heteroarilos inhibidores de las proteínas ras mutantes de g12c
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
EP3935060A1 (en) 2022-01-12
UY38602A (es) 2020-09-30
JP7453989B2 (ja) 2024-03-21
PE20220140A1 (es) 2022-01-27
MA55198A (fr) 2022-01-12
AU2020231045B2 (en) 2023-03-16
MX2021010674A (es) 2021-09-28
TW202100532A (zh) 2021-01-01
CN113508118A (zh) 2021-10-15
IL285761B1 (en) 2024-08-01
CL2021002296A1 (es) 2022-04-29
DOP2021000183A (es) 2021-09-30
US20220204527A1 (en) 2022-06-30
ZA202106192B (en) 2022-08-31
CN113508118B (zh) 2024-07-19
JP2022523981A (ja) 2022-04-27
CA3131156A1 (en) 2020-09-10
EP3935060C0 (en) 2023-11-15
AU2020231045A1 (en) 2021-10-28
KR20210135539A (ko) 2021-11-15
CR20210504A (es) 2022-02-08
IL285761A (en) 2021-10-31
ECSP21073246A (es) 2021-11-30
SG11202109451TA (en) 2021-09-29
EP3935060B1 (en) 2023-11-15
WO2020178282A1 (en) 2020-09-10
BR112021017408A2 (pt) 2022-01-18
CO2021012381A2 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12019501724A1 (en) Estrogen receptor modulators
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
ZA202400595B (en) Spirocyclic compounds
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
TW201613864A (en) Novel compounds
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
MX2016010745A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina.
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
MX2021015727A (es) Derivados de piridin-3-ilo.
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
EA202192366A1 (ru) Конденсированные трициклические соединения, применимые в качестве противораковых средств
EA202092600A1 (ru) Тетрациклические гетероарильные соединения